Achieve Life Sciences (ACHV:NASDAQ) Annual Reports & Investor Relations Material

Overview

VANCOUVER, Canada—Clinical-stage pharmaceutical company Achieve Life Sciences, Inc. has developed a promising solution for smoking cessation and nicotine addiction in Canada, the United States, and the United Kingdom. The company's cytisinicline, a plant-based alkaloid, reduces the severity of nicotine withdrawal symptoms by interacting with nicotine receptors in the brain. Achieve Life Sciences, Inc. boasts a solid license agreement with Sopharma AD and the University of Bristol.

Annual Reports

Frequently Asked Questions

What is Achieve Life Sciences's ticker?

Achieve Life Sciences's ticker is ACHV

What exchange is Achieve Life Sciences traded on?

The company's shares trade on the NASDAQ stock exchange

Where are Achieve Life Sciences's headquarters?

They are based in Seattle, Washington

How many employees does Achieve Life Sciences have?

There are 11-50 employees working at Achieve Life Sciences

What is Achieve Life Sciences's website?

It is achievelifesciences.com

What type of sector is Achieve Life Sciences?

Achieve Life Sciences is in the Healthcare sector

What type of industry is Achieve Life Sciences?

Achieve Life Sciences is in the Biotechnology industry

Who are Achieve Life Sciences's peers and competitors?

The following five companies are Achieve Life Sciences's industry peers:

- I-MAB

- Alexion Pharmaceuticals

- Cyclerion Therapeutics, Inc.

- NewMarket

- Arcutis Biotherapeutics